pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,890 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1757Endpoints1368Fierce Biotech691BioSpace682BioPharma Dive517raps227onclive165fda recalls110fda medwatch
therapy area
allOncology12198Rare Disease3151Immunology2838Cardiology2654Pulmonology2129Hematology2125Vaccines
  • Alethio Therapeutics raises $90 million Series A to develop antibody for essential thrombocythemia
    Alethio Therapeutics, a spinout from the University of Oxford, announced a $90 million Series A financing round. The capital will fund the company’s lead program, an antibody designed to treat ess…
    Endpoints · 4d agoDealPositive↗ source
  • T-Therapeutics raises $133 million from Sanofi, J&J, Merck KGaA and Eli Lilly for TCR cancer and autoimmune programs
    T-Therapeutics, a UK biotech focused on T-cell receptor therapies for cancer and autoimmune diseases, announced it has raised $133 million in financing. The round is led by Sanofi with participati…
    Endpoints · 4d agoDealPositive↗ source
← prev
page 5 of 196
next →
104
globenewswire health73
fda press58
1775
Psychiatry & CNS1195
Ophthalmology996
Endocrinology & Metabolism768
Pain768
Nephrology753
  • One in Five Biopharma Workers Have Been Laid Off Multiple Times, Survey Shows
    A recent BioSpace LinkedIn poll found that 64% of biotech and pharma professionals have been laid off in the past five years, and 22% have experienced job loss at least twice. Those who have faced…
    BioSpace · 4d agoLayoffsNegative↗ source
  • MDCG issues guidance on clinical evidence for orphan in-vitro diagnostics
    The Medical Device Coordination Group (MDCG) has published new guidance that explains how clinical evidence requirements apply to orphan in-vitro diagnostics (IVDs). The document is intended to he…
    raps · 4d agoRegulatoryNeutral↗ source
  • PhRMA spent roughly $59 million on search ads to shape public views on drug pricing
    PhRMA, the trade group for U.S. drug makers, spent about $59 million on search advertising over a recent seven‑year period to influence how Americans perceive prescription‑drug costs. Roughly $32…
    STAT · 3d agoNeutral↗ source
  • New treatments for preeclampsia move closer to patients
    Emily Chaddock’s experience highlights the danger of severe preeclampsia, a pregnancy complication that can threaten both mother and baby. At 27 weeks she developed the condition, leading to a rapi…
    Endpoints · 3d agoPositive↗ source
  • Democratic doctors celebrate gains as MAHA’s future remains uncertain after election
    The STAT+ D.C. Diagnosis newsletter reports that doctors aligned with the Democratic Party secured notable wins in recent political battles. At the same time, the Medicare for All (MAHA) initiativ…
    STAT · 4d agoNeutral↗ source
  • ProMis shares tumble after competitor's Alzheimer trial failure, CEO calls reaction overblown
    ProMis Neurosciences, developer of an amyloid‑targeting Alzheimer’s therapy, saw its stock plunge sharply last week. The decline came after Acumen Pharmaceuticals announced that its own amyloid‑ta…
    STAT · 4d agoNegative↗ source
  • Generate Biomedicines CEO touts AI-driven shrinkage of CAR-T cell engines as huge opportunity
    Generate Biomedicines' chief executive highlighted a "huge opportunity" after the company applied Anthropic's Claude AI platform to make its CAR‑T cell engines smaller. The Flagship‑founded biotec…
    Fierce Biotech · 4d agoPositive↗ source
  • Health systems grapple with AI chatbot use, some block tools while others consider in-house solutions
    Free AI chatbots designed for clinicians, such as OpenEvidence, Doximity Ask and ChatGPT for Clinicians, have become popular, with hundreds of thousands of doctors turning to them for clinical guid…
    STAT · 4d agoRegulatoryNeutral↗ source
  • Agios to cut over 202 R&D positions as it awaits FDA decision on sickle cell drug
    Agios Pharmaceuticals said it will eliminate more than 100 research and development positions by the end of 2026, cutting its R&D workforce by roughly 35% from 2025 levels. The company entered the…
    Fierce Biotech · 4d agoLayoffsNegative↗ source
  • Cloudbreak Pharma’s Phase 3 Eye Drop Shows Significant Benefit in Pterygium Trial
    Cloudbreak Pharma reported that its phase 3 trial of CBT-001, a multi‑kinase inhibitor eye drop for pterygium, met both co‑primary endpoints. The study compared two doses of CBT-001 given twice da…
    Fierce Biotech · 4d agoPositive readoutPositive↗ source
  • Experts urge streamlined EU AI framework and higher regulatory literacy for healthcare products
    Experts speaking at the RAPS AI in Regulatory Conference in Barcelona called for a more streamlined artificial intelligence framework for healthcare products across Europe. They said the current r…
    raps · 4d agoRegulatoryNeutral↗ source
  • FDA official says midterm elections unlikely to delay user fee reauthorization for FY 2028-2032
    A senior FDA official indicated that the recent midterm election results are not expected to interfere with the upcoming renewal of the agency’s user fee contracts covering fiscal years 2028 throug…
    raps · 4d agoRegulatoryNeutral↗ source
  • AAFP chief urges Congress to add oversight to CDC vaccine advisory panel
    Shawn Martin, CEO of the American Academy of Family Physicians, said the CDC’s Advisory Committee on Immunization Practices (ACIP) has faced more than a year of turmoil. He is urging Congress to e…
    Endpoints · 3d agoRegulatoryNeutral↗ source
  • STAT+: Beyond statins, one drug lowered heart attack risk by 20%
    A new study could help doctors figure out what medicine to prescribe for cholesterol when statins don't cut it: It's “answering a really challenging clinical question."
    STAT · 4d agoRegulatoryNeutral↗ source
  • Vivoryon reclaims Chinese rights to kidney disease drug amid cash crunch
    Vivoryon Therapeutics, a Munich-based biotech, has taken back the rights to develop its kidney disease candidate in China after a licensing arrangement with Simcere Pharmaceuticals. The original 2…
    Fierce Biotech · 4d agoDealNeutral↗ source
  • Trump administration ends contracts with two No Surprises Act arbitrators over performance failures
    The federal government announced that two organizations that handle disputes under the No Surprises Act will no longer be allowed to accept new cases, saying they failed to meet required performanc…
    STAT · 3d agoRegulatoryNegative↗ source
  • Ellipsis Health acquires Kouper Health to expand AI voice call capabilities
    Ellipsis Health, a startup that builds voice-based artificial intelligence tools for healthcare, announced it has purchased Kouper Health. The deal reflects growing interest in AI systems that can…
    Endpoints · 4d agoDealNeutral↗ source
  • Medicare postpones controversial rule that bars hospitals from using third-party remote patient monitoring services
    Medicare announced it will finalize a proposal that delays an update to its remote patient monitoring (RPM) rule, despite strong opposition. The rule would prohibit hospitals and other providers f…
    STAT · 4d agoRegulatoryNegative↗ source
  • Podcast explores how intratumoral injections may spark systemic cancer immunity
    In a recent episode of BioSpace's Denatured podcast, host Jennifer C. Smith-Parker spoke with Lewis Bender, CEO of Intensity Therapeutics, and Paul-Peter Tak, president and CEO of Candel Therapeuti…
    BioSpace · 4d agoNeutral↗ source
  • BioSpace lists top 12 biopharma employers hiring in July 2026
    BioSpace released a list of the twelve biopharma firms with the most job postings in July 2026. The list includes AbbVie, Regeneron, Amgen, Eli Lilly, Sanofi, Novo Nordisk, Moderna, Insmed, Freder…
    BioSpace · 4d agoNeutral↗ source
  • Ballot measures on abortion, marijuana and transgender youth care highlight political divides in 2026 midterms
    Voters in the 2026 midterm elections faced a slate of state health policy ballot measures that addressed abortion rights, marijuana legalization, science funding bonds and care for transgender yout…
    STAT · 3d agoNeutral↗ source
  • MAHA movement faces electoral defeat as its political influence wanes
    The opinion piece declares that the original MAHA initiative, dubbed MAHA 1.0, has effectively ended after recent midterm elections, and suggests a new phase, MAHA 2.0, may emerge. At least eleven…
    STAT · 3d agoNegative↗ source
  • Neurosurgeon reflects on the difference between pain and suffering in chronic back pain patients
    Stephen Doran, a neurosurgeon and author, writes an opinion piece about how pain and suffering are distinct experiences for patients. He recounts a recent visit with a 60‑plus veteran who had endu…
    STAT · 4d agoNeutral↗ source